Targeted drug discovery for pediatric leukemia

Frontiers in Oncology

Volumn 3 JUL, Issue , 2013, Pages

  Napper, Andrew D ^a   Watson, Venita G ^a,b  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b Department of Structural Biology   (United States)

Author keywords

Drug discovery; Lead optimization; Leukemia; Medicinal chemistry; Molecular target; Targeted therapy

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL] UREA; 1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 8 [4 (1 AMINOCYCLOBUTYL) PHENYL] 9 PHENYL 1, 2, 4 TRIAZOLO [3, 4 F] [1, 6] NAPHTHYRIDIN 3 (2H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALISERTIB; ANTILEUKEMIC AGENT; AR 42; AZACITIDINE; BORTEZOMIB; BPR1J 097; CYCLOPHOSPHAMIDE; DACTOLISIB; DASATINIB; ETOPOSIDE; EVEROLIMUS; IMATINIB; LESTAURTINIB; METHOTREXATE; MIDOSTAURIN; NILOTINIB; OBATOCLAX; PACRITINIB; PANOBINOSTAT; PLERIXAFOR; PONATINIB; PRACINOSTAT; QUIZARTINIB; RAPAMYCIN; RUXOLITINIB; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CELL CYCLE ARREST; CELL PROLIFERATION; CHILDHOOD LEUKEMIA; DRUG EFFICACY; DRUG POTENTIATION; GENETIC TRANSCRIPTION; HISTONE UBIQUITINATION; HUMAN; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SURVIVAL;

EID: 84891121138     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00170     Document Type: Review

References (98)

1. Anglin, J. L., Deng, L., Yao, Y., Cai, G., Liu, Z., Jiang, H., et al. (2012). Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L. J. Med. Chem. 55, 8066-8074. doi:10.1021/jm300917h
2. Attar, E. C. (2012). Get out-and stay out. Blood 119, 3869-3870. doi:10.1182/blood-2012-02-410357
3. Ayton, P. M., and Cleary, M. L. (2003). Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 17, 2298-2307. doi:10.1101/gad.1111603
4. Barr, R. D. (2010). Imatinib mesylate in children and adolescents with cancer. Pediatr. Blood Cancer 55, 18-25. doi:10.1002/pbc.22484
5. Barrett, D., Brown, V. I., Grupp, S. A., and Teachey, D. T. (2012). Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr. Drugs 14, 299-316. doi:10.2165/11594740-000000000-00000
6. Bastian, L., Hof, J., Pfau, M., Fichtner, I., Eckert, C., Henze, G., et al. (2013). Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-kappaB. Clin. Cancer Res. 19, 1445-1457. doi:10.1158/1078-0432.CCR-12-1511
7. Bavetsias, V., Crumpler, S., Sun, C., Avery, S., Atrash, B., Faisal, A., et al. (2012). Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. J. Med. Chem. 55, 8721-8734. doi:10.1021/jm300952s
8. Bernt, K. M., and Armstrong, S. A. (2011). Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am. Soc. Hematol. Educ. Program 2011, 354-360. doi:10.1182/asheducation-2011.1.354
9. Brandwein, J. M. (2011). Treatment of acute lymphoblastic leukemia in adolescents and young adults. Curr. Oncol. Rep. 13, 371-378. doi:10.1007/s11912-011-0185-9
10. Brown, P., Hunger, S. P., Smith, F. O., Carroll, W. L., and Reaman, G. H. (2009). Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Rev. Hematol. 2, 145. doi:10.1586/ehm.09.1
11. Brown, P., Levis, M., McIntyre, E., Griesemer, M., and Small, D. (2006). Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia 20, 1368-1376. doi:10.1038/sj.leu.2404277
12. Chang, M. J., Wu, H., Achille, N. J., Reisenauer, M. R., Chou, C. W., Zeleznik-Le, N. J., et al. (2010). Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 70, 10234-10242. doi:10.1158/0008-5472.CAN-10-3294
13. Chen, L., Deshpande, A. J., Banka, D., Bernt, K. M., Dias, S., Buske, C., et al. (2012). Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia 27, 813-822. doi:10.1038/leu.2012.327
14. Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., et al. (2012). Ponatinib in refractory Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 367, 2075-2088. doi:10.1056/NEJMoa1205127
15. Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., et al. (2011). Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65. doi:10.1016/j.ccr.2011.06.009
16. Daver, N., and Cortes, J. (2012). Molecular targeted therapy in acute myeloid leukemia. Hematology 17(Suppl. 1), S59-S62. doi:10.1179/102453312X13336169155619
17. Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W. I., et al. (2011). Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533. doi:10.1038/nature10509
18. Deshpande, A. J., Bradner, J., and Armstrong, S. A. (2012). Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol. 33, 563-570. doi:10.1016/j.it.2012.06.002
19. Deshpande, A. J., Chen, L., Fazio, M., Sinha, A. U., Bernt, K. M., Banka, D., et al. (2013). Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 121, 2533-2541. doi:10.1182/blood-2012-11-465120
20. Devaiah, B. N., Lewis, B. A., Cherman, N., Hewitt, M. C., Albrecht, B. K., Robey, P. G., et al. (2012). BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc. Natl. Acad. Sci. U.S.A. 109, 6927-6932. doi:10.1073/pnas.1120422109
21. Erfurth, F., Hemenway, C. S., De Erkenez, A. C., and Domer, P. H. (2004). MLL fusion partners AF4 and AF9 interact at subnuclear foci. Leukemia 18, 92-102. doi:10.1038/sj.leu.2403200
22. Faber, J., Krivtsov, A. V., Stubbs, M. C., Wright, R., Davis, T. N., Van Den Heuvel-Eibrink, M., et al. (2009). HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 113, 2375-2385. doi:10.1182/blood-2007-09-113597
23. Fandy, T. E. (2009). Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Curr. Med. Chem. 16, 2075-2085. doi:10.2174/092986709788612738
24. Farag, S. S. (2011). The potential role of aurora kinase inhibitors in haematological malignancies. Br. J. Haematol. 155, 561-579. doi:10.1111/j.1365-2141.2011.08898.x
25. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., et al. (2010). Selective inhibition of BET bromodomains. Nature 468, 1067-1073. doi:10.1038/nature09504
26. Food and Drug Administration. (2013). FDA Approves Gleevec for Children with Acute Lymphoblastic Leukemia. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336868.htm [accessed March 17, 2013].
27. Fulda, S. (2009). Exploiting apoptosis pathways for the treatment of pediatric cancers. Pediatr. Blood Cancer 53, 533-536. doi:10.1002/pbc.21922
28. Giannini, G., Cabri, W., Fattorusso, C., and Rodriquez, M. (2012). Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med. Chem. 4, 1439-1460. doi:10.4155/fmc.12.80
29. Grembecka, J., He, S., Shi, A., Purohit, T., Muntean, A. G., Sorenson, R. J., et al. (2012). Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 8, 277-284. doi:10.1038/nchembio.773
30. Grunwald, M. R., and Levis, M. J. (2013). FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int. J. Hematol. 97, 683-694. doi:10.1007/s12185-013-1334-8
31. Hartsink-Segers, S. A., Zwaan, C. M., Exalto, C., Luijendijk, M. W., Calvert, V. S., Petricoin, E. F., et al. (2013). Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia 27, 560-568. doi:10.1038/leu.2012.256
32. Hatlen, M. A., Wang, L., and Nimer, S. D. (2012). AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches. Front. Med. 6, 248-262. doi:10.1007/s11684-012-0206-6
33. Herrmann, H., Blatt, K., Shi, J., Gleixner, K. V., Cerny-Reiterer, S., Mullauer, L., et al. (2012). Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia AML. Oncotarget 3, 1588-1599.
34. Hollink, I. H., van den Heuvel-Eibrink, M. M., Arentsen-Peters, S. T., Pratcorona, M., Abbas, S., Kuipers, J. E., et al. (2011). NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 118, 3645-3656. doi:10.1182/blood-2011-04-346643
35. Horton, T. M., Pati, D., Plon, S. E., Thompson, P. A., Bomgaars, L. R., Adamson, P. C., et al. (2007). A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a children's oncology group study. Clin. Cancer Res. 13, 1516-1522. doi:10.1158/1078-0432.CCR-06-2173
36. Hunger, S. P. (2011). Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia. Hematology Am. Soc. Hematol. Educ. Program 2011, 361-365. doi:10.1182/asheducation-2011.1.361
37. Huret, J. L., Dessen, P., and Bernheim, A. (2001). An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners. Leukemia 15, 987-989. doi:10.1038/sj.leu.2402135
38. Jaju, R. J., Fidler, C., Haas, O. A., Strickson, A. J., Watkins, F., Clark, K., et al. (2001). A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 98, 1264-1267. doi:10.1182/blood.V98.4.1264
39. Jayanthan, A., Cooper, T. M., Hoeksema, K. A., Lotfi, S., Woldum, E., Lewis, V. A., et al. (2013). Occurrence and modulation of therapeutic targets of aurora kinase inhibition in pediatric acute leukemia cells. Leuk. Lymphoma 54, 1505-1516. doi:10.3109/10428194.2012.752079
40. Kampa-Schittenhelm, K. M., Heinrich, M. C., Akmut, F., Dohner, H., Dohner, K., and Schittenhelm, M. M. (2013). Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3,-PDGFRA and-KIT isoforms. Mol. Cancer 12, 19. doi:10.1186/1476-4598-12-19
41. Kang, M. H., Kang, Y. H., Szymanska, B., Wilczynska-Kalak, U., Sheard, M. A., Harned, T. M., et al. (2007). Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110, 2057-2066. doi:10.1182/blood-2007-03-080325
42. Kersey, J. H. (1997). Fifty years of studies of the biology and therapy of childhood leukemia. Blood 90, 4243-4251.
43. Krivtsov, A. V., and Armstrong, S. A. (2007). MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 7, 823-833. doi:10.1038/nrc2253
44. Kurmasheva, R. T., and Houghton, P. J. (2007). Pediatric oncology. Curr. Opin. Chem. Biol. 11, 424-432. doi:10.1016/j.cbpa.2007.05.037
45. Lee-Sherick, A. B., Eisenman, K. M., Sather, S., McGranahan, A., Armistead, P. M., McGary, C. S., et al. (2013). Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene. doi:10.1038/onc.2013.40. [Epub ahead of print].
46. Lin, W. H., Jiaang, W. T., Chen, C. W., Yen, K. J., Hsieh, S. Y., Yen, S. C., et al. (2012). BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. Br. J. Cancer 106, 475-481. doi:10.1038/bjc.2011.564
47. Lock, R., Carol, H., Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R., et al. (2008). Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr. Blood Cancer 50, 1181-1189. doi:10.1002/pbc.21433
48. Lucas, D. M., Alinari, L., West, D. A., Davis, M. E., Edwards, R. B., Johnson, A. J., et al. (2010). The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS ONE 5:e10941. doi:10.1371/journal.pone.0010941
49. Lyko, F., and Brown, R. (2005). DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J. Natl. Cancer Inst. 97, 1498-1506. doi:10.1093/jnci/dji311
50. Mackall, C. L. (2011). In search of targeted therapies for childhood cancer. Front. Oncol. 1:18. doi:10.3389/fonc.2011.00018
51. Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., et al. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863. doi:10.1158/1535-7163.MCT-08-0017
52. Martelli, A. M., Chiarini, F., Evangelisti, C., Cappellini, A., Buontempo, F., Bressanin, D., et al. (2012). Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 3, 371-394.
53. Maude, S. L., Tasian, S. K., Vincent, T., Hall, J. W., Sheen, C., Roberts, K. G., et al. (2012). Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 120, 3510-3518. doi:10.1182/blood-2012-03-415448
54. McGinty, R. K., Kim, J., Chatterjee, C., Roeder, R. G., and Muir, T. W. (2008). Chemically ubiquitylated histone H2B stimulates hDot1L-mediated intranucleosomal methylation. Nature 453, 812-816. doi:10.1038/nature06906
55. McGinty, R. K., Kohn, M., Chatterjee, C., Chiang, K. P., Pratt, M. R., and Muir, T. W. (2009). Structure-activity analysis of semisynthetic nucleosomes: mechanistic insights into the stimulation of Dot1L by ubiquitylated histone H2B. ACS Chem. Biol. 4, 958-968. doi:10.1021/cb9002255
56. Meyer, C., Schneider, B., Jakob, S., Strehl, S., Attarbaschi, A., Schnittger, S., et al. (2006). The MLL recombinome of acute leukemias. Leukemia 20, 777-784. doi:10.1038/sj.leu.2404150
57. Min, J., Feng, Q., Li, Z., Zhang, Y., and Xu, R. M. (2003). Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell 112, 711-723. doi:10.1016/S0092-8674(03)00114-4
58. Morishita, M., and di Luccio, E. (2011). Cancers and the NSD family of histone lysine methyltransferases. Biochim. Biophys. Acta 1816, 158-163. doi:10.1016/j.bbcan.2011.05.004
59. Mueller, D., Garcia-Cuellar, M. P., Bach, C., Buhl, S., Maethner, E., and Slany, R. K. (2009). Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol. 7:e1000249. doi:10.1371/journal.pbio.1000249
60. Mummery, A., Narendran, A., and Lee, K. Y. (2011). Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia. Curr. Cancer Drug Targets 11, 882-893. doi:10.2174/156800911796798922
61. Muntean, A. G., and Hess, J. L. (2012). The pathogenesis of mixed-lineage leukemia. Annu. Rev. Pathol. 7, 283-301. doi:10.1146/annurev-pathol-011811-132434
62. National Cancer Institute. (2010). SEER (Surveillance, Epidemiology, and End Results) Statistics Review, 1975-2007.
63. National Cancer Institute. (2013). Clinical Trials. Available at: http://www.cancer.gov/clinicaltrials [accessed March 17, 2013].
64. Nguyen, A. T., Taranova, O., He, J., and Zhang, Y. (2011). DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 117, 6912-6922. doi:10.1182/blood-2011-02-334359
65. Niewerth, D., Dingjan, I., Cloos, J., Jansen, G., and Kaspers, G. (2013). Proteasome inhibitors in acute leukemia. Expert Rev. Anticancer Ther. 13, 327-337. doi:10.1586/era.13.4
66. Novotny-Diermayr, V., Hart, S., Goh, K. C., Cheong, A., Ong, L. C., Hentze, H., et al. (2012). The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J. 2, e69. doi:10.1038/bcj.2012.14
67. Ott, C. J., Kopp, N., Bird, L., Paranal, R. M., Qi, J., Bowman, T., et al. (2012). BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 120, 2843-2852. doi:10.1182/blood-2012-02-413021
68. Park, I. K., Mishra, A., Chandler, J., Whitman, S. P., Marcucci, G., and Caligiuri, M. A. (2013). Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Blood 121, 2064-2073. doi:10.1182/blood-2012-07-444018
69. Park, S., Chapuis, N., Tamburini, J., Bardet, V., Cornillet-Lefebvre, P., Willems, L., et al. (2010). Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 95, 819-828. doi:10.3324/haematol.2009.013797
70. Peled, A., and Tavor, S. (2013). Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics 3, 34-39. doi:10.7150/thno.5150
71. Popovic, R., and Licht, J. D. (2012). Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov. 2, 405-413. doi:10.1158/2159-8290.CD-12-0076
72. Pui, C. H., Carroll, W. L., Meshinchi, S., and Arceci, R. J. (2011a). Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol. 29, 551-565. doi:10.1200/JCO.2010.30.7405
73. Pui, C. H., Gajjar, A. J., Kane, J. R., Qaddoumi, I. A., and Pappo, A. S. (2011b). Challenging issues in pediatric oncology. Nat. Rev. Clin. Oncol. 8, 540-549. doi:10.1038/nrclinonc.2011.95
74. Robinson, B.W., Devidas, M., Carroll, A.J., Harvey, R.C., Heerema, N.A., Willman, C.L., et al. (2009). "Specific MLL partner genes in infant acute lymphoblastic leukemia (ALL) associated with outcome are linked to age and white blood cell count (WBC) at diagnosis: a report on the Children's Oncology Group (COG) P9407 trial," in American Society of Hematology Annual Meeting and Exposition, New Orleans, LA.
75. Schult, C., Dahlhaus, M., Glass, A., Fischer, K., Lange, S., Freund, M., et al. (2012). The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Anticancer Res. 32, 463-474.
76. Schultz, K. R., Bowman, W. P., Aledo, A., Slayton, W. B., Sather, H., Devidas, M., et al. (2009). Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J. Clin. Oncol. 27, 5175-5181. doi:10.1200/JCO.2008.21.2514
77. Sexauer, A., Perl, A., Yang, X., Borowitz, M., Gocke, C., Rajkhowa, T., et al. (2012). Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood 120, 4205-4214. doi:10.1182/blood-2012-01-402545
78. Sison, E. A., Rau, R. E., McIntyre, E., Li, L., Small, D., and Brown, P. (2013). MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. Br. J. Haematol. 160, 785-797. doi:10.1111/bjh.12205
79. Slany, R. K. (2009). The molecular biology of mixed lineage leukemia. Haematologica 94, 984-993. doi:10.3324/haematol.2008.002436
80. Somervaille, T. C., and Cleary, M. L. (2010). Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells? Int. J. Hematol. 91, 735-741. doi:10.1007/s12185-010-0579-8
81. Srinivasan, R. S., Nesbit, J. B., Marrero, L., Erfurth, F., Larussa, V. F., and Hemenway, C. S. (2004). The synthetic peptide PFWT disrupts AF4-AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells. Leukemia 18, 1364-1372. doi:10.1038/sj.leu.2403415
82. Stubbs, M. C., and Armstrong, S. A. (2007). FLT3 as a therapeutic target in childhood acute leukemia. Curr. Drug Targets 8, 703-714. doi:10.2174/138945007780830782
83. Swords, R., Freeman, C., and Giles, F. (2012). Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 26, 2176-2185. doi:10.1038/leu.2012.114
84. Sykes, S. M., Lane, S. W., Bullinger, L., Kalaitzidis, D., Yusuf, R., Saez, B., et al. (2011). AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 146, 697-708. doi:10.1016/j.cell.2011.07.032
85. Thiel, A. T., Huang, J., Lei, M., and Hua, X. (2012). Menin as a hub controlling mixed lineage leukemia. Bioessays 34, 771-780. doi:10.1002/bies.201200007
86. Urtishak, K. A., Edwards, A. Y., Wang, L. S., Hudome, A., Robinson, B. W., Barrett, J. S., et al. (2013). Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia (ALL). Blood. 121, 2689-2703. doi:10.1182/blood-2012-04-425033
87. Uy, G. L., Rettig, M. P., Motabi, I. H., McFarland, K., Trinkaus, K. M., Hladnik, L. M., et al. (2012). A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 119, 3917-3924. doi:10.1182/blood-2011-10-383406
88. Vu, L. P., Luciani, L., and Nimer, S. D. (2013). Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential. Int. J. Hematol. 97, 198-209. doi:10.1007/s12185-012-1247-y
89. Wagner, E. J., and Carpenter, P. B. (2012). Understanding the language of Lys36 methylation at histone H3. Nat. Rev. Mol. Cell Biol. 13, 115-126. doi:10.1038/nrm3274
90. Wang, E., Kawaoka, S., Yu, M., Shi, J., Ni, T., Yang, W., et al. (2013). Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia. Proc. Natl. Acad. Sci. U.S.A. 110, 3901-3906. doi:10.1073/pnas.1301045110
91. Wang, G. G., Cai, L., Pasillas, M. P., and Kamps, M. P. (2007). NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat. Cell Biol. 9, 804-812. doi:10.1038/ncb1608
92. Watson, V. G., Drake, K. M., Peng, Y., and Napper, A. D. (2013). Development of a high-throughput screening-compatible assay for the discovery of inhibitors of the AF4-AF9 interaction using alphascreen technology. Assay Drug Dev. Technol. 11, 253-268. doi:10.1089/adt.2012.495
93. Weisberg, E., Liu, Q., Nelson, E., Kung, A. L., Christie, A. L., Bronson, R., et al. (2012). Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia 26, 2233-2244. doi:10.1038/leu.2012.96
94. Weisberg, E., Liu, Q., Zhang, X., Nelson, E., Sattler, M., Liu, F., et al. (2013). Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLoS ONE 8:e56473. doi:10.1371/journal.pone.0056473
95. Yao, Y., Chen, P., Diao, J., Cheng, G., Deng, L., Anglin, J. L., et al. (2011). Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. J. Am. Chem. Soc. 133, 16746-16749. doi:10.1021/ja206312b
96. Yu, W., Chory, E. J., Wernimont, A. K., Tempel, W., Scopton, A., Federation, A., et al. (2012). Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat. Commun. 3, 1288. doi:10.1038/ncomms2304
97. Zhang, Y., Chen, A., Yan, X. M., and Huang, G. (2012). Disordered epigenetic regulation in MLL-related leukemia. Int. J. Hematol. 96, 428-437. doi:10.1007/s12185-012-1180-0
98. Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., et al. (2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528. doi:10.1038/nature10334